These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 9873513)
1. Isoxazolylthioamides as potential immunosuppressants a combinatorial chemistry approach. Albert R; Knecht H; Andersen E; Hungerford V; Schreier MH; Papageorgiou C Bioorg Med Chem Lett; 1998 Aug; 8(16):2203-8. PubMed ID: 9873513 [TBL] [Abstract][Full Text] [Related]
2. Pyrazole bioisosteres of leflunomide as B-cell immunosuppressants for xenotransplantation and chronic rejection: scope and limitations. Papageorgiou C; Albert R; Floersheim P; Lemaire M; Bitch F; Weber HP; Andersen E; Hungerford V; Schreier MH J Med Chem; 1998 Aug; 41(18):3530-8. PubMed ID: 9719606 [TBL] [Abstract][Full Text] [Related]
3. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Davis JP; Cain GA; Pitts WJ; Magolda RL; Copeland RA Biochemistry; 1996 Jan; 35(4):1270-3. PubMed ID: 8573583 [TBL] [Abstract][Full Text] [Related]
4. Dihydroorotate dehydrogenase is a target for the biological effects of leflunomide. Williamson RA; Yea CM; Robson PA; Curnock AP; Gadher S; Hambleton AB; Woodward K; Bruneau JM; Hambleton P; Spinella-Jaegle S; Morand P; Courtin O; Sautés C; Westwood R; Hercend T; Kuo EA; Ruuth E Transplant Proc; 1996 Dec; 28(6):3088-91. PubMed ID: 8962196 [No Abstract] [Full Text] [Related]
5. Structure-activity relationships (SAR) of some tetracyclic heterocycles related to the immunosuppressive agent Brequinar Sodium. Pitts WJ; Jetter JW; Pinto DJ; Orwat MJ; Batt DG; Sherk SR; Petraitis JJ; Jacobson IC; Copeland RA; Dowling RL; Jaffee BD; Gardner TL; Jones EA; Magolda RL Bioorg Med Chem Lett; 1998 Feb; 8(3):307-12. PubMed ID: 9871675 [TBL] [Abstract][Full Text] [Related]
6. 3D-QSAR studies on a series of dihydroorotate dehydrogenase inhibitors: analogues of the active metabolite of leflunomide. Li SL; He MY; Du HG Int J Mol Sci; 2011; 12(5):2982-93. PubMed ID: 21686163 [TBL] [Abstract][Full Text] [Related]
7. Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives. Knecht W; Löffler M Biochem Pharmacol; 1998 Nov; 56(9):1259-64. PubMed ID: 9802339 [TBL] [Abstract][Full Text] [Related]
8. Mechanism of action of leflunomide: in vivo uridine administration reverses its inhibition of lymphocyte proliferation. Silva HT; Cao W; Shorthouse R; Morris RE Transplant Proc; 1996 Dec; 28(6):3082-4. PubMed ID: 8962193 [No Abstract] [Full Text] [Related]
10. 1,2,5-Oxadiazole analogues of leflunomide and related compounds. Giorgis M; Lolli ML; Rolando B; Rao A; Tosco P; Chaurasia S; Marabello D; Fruttero R; Gasco A Eur J Med Chem; 2011 Jan; 46(1):383-92. PubMed ID: 21109332 [TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo effects of leflunomide, brequinar, and cyclosporine on pyrimidine biosynthesis. Silva HT; Cao W; Shorthouse RA; Löffler M; Morris RE Transplant Proc; 1997; 29(1-2):1292-3. PubMed ID: 9123312 [No Abstract] [Full Text] [Related]
12. Cell cycle regulation and inhibition of de novo pyrimidine biosynthesis by leflunomide. Schorlemmer HU; Milbert U; Zeitter D; Haun G; Wunschel M; Bartlett RR Inflamm Res; 1999 Dec; 48 Suppl 2():S115-6. PubMed ID: 10667841 [No Abstract] [Full Text] [Related]
13. Synthesis and immunosuppressant activity of pyrazole carboxamides. Wang AX; Xie Q; Lane B; Mollison KW; Hsieh GC; Marsh K; Sheets MP; Luly JR; Coghlan MJ Bioorg Med Chem Lett; 1998 Oct; 8(19):2787-92. PubMed ID: 9873623 [TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation of novel substituted benzamide derivatives bearing a 1,2,3-triazole moiety as potent human dihydroorotate dehydrogenase inhibitors. Lu K; Cai L; Zhang X; Wu G; Xu C; Zhao Y; Gong P Bioorg Chem; 2018 Feb; 76():528-537. PubMed ID: 29316525 [TBL] [Abstract][Full Text] [Related]
15. Dihydroorotate dehydrogenase. Profile of a novel target for antiproliferative and immunosuppressive drugs. Löffler M; Grein K; Knecht W; Klein A; Bergjohann U Adv Exp Med Biol; 1998; 431():507-13. PubMed ID: 9598119 [No Abstract] [Full Text] [Related]
16. A new rational hypothesis for the pharmacophore of the active metabolite of leflunomide, a potent immunosuppressive drug. Bertolini G; Aquino M; Biffi M; d'Atri G; Di Pierro F; Ferrario F; Mascagni P; Somenzi F; Zaliani A; Leoni F J Med Chem; 1997 Jun; 40(13):2011-6. PubMed ID: 9207942 [TBL] [Abstract][Full Text] [Related]
17. Inactivation of protein tyrosine phosphatases by dietary isothiocyanates. Lewis SM; Li Y; Catalano MJ; Laciak AR; Singh H; Seiner DR; Reilly TJ; Tanner JJ; Gates KS Bioorg Med Chem Lett; 2015 Oct; 25(20):4549-52. PubMed ID: 26338358 [TBL] [Abstract][Full Text] [Related]
18. Human dihydroorotate dehydrogenase inhibitors, a novel approach for the treatment of autoimmune and inflammatory diseases. Leban J; Vitt D Arzneimittelforschung; 2011; 61(1):66-72. PubMed ID: 21355448 [TBL] [Abstract][Full Text] [Related]
19. Syntheses, immunosuppressive activity, and structure-activity relationships of myriocin analogs, 2-epi-myriocin, 14-deoxomyriocin, Z-14-deoxyomyriocin, and nor-deoxomyriocins. Yoshikawa M; Yokokawa Y; Okuno Y; Yagi N; Murakami N Chem Pharm Bull (Tokyo); 1995 Oct; 43(10):1647-53. PubMed ID: 8536338 [TBL] [Abstract][Full Text] [Related]
20. Isolation and identification of a C39 demethylated metabolite of rapamycin from pig liver microsomes and evaluation of its immunosuppressive activity. Nickmilder MJ; Latinne D; De Houx JP; Verbeeck RK; Lhoëst GJ Clin Chem; 1998 Mar; 44(3):532-8. PubMed ID: 9510858 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]